A partner of Meriden’s Protein Sciences Corp. has asked the Japanese government for approval to market PSC’s influenza vaccine in that country, the company announced.
The filing by Tokyo-based Astellas Pharma and its partner UMN Pharma — which holds exclusive rights to develop and market Flublok in Japan — will result in a “significant” milestone payment for Protein Sciences, though it did not disclose the amount.
The application is based mainly on the results of a series of clinical trials conducted in Japan, the companies said.
UMN also has exclusive license rights to the recombinant protein-based vaccine, as well as a pandemic version called Panblok, in China, Korea, Hong Kong, Taiwan and Singapore, PSC said.
ADVERTISEMENT
Read more
